Abstract: An electronic device, while displaying messaging user interface that includes a conversation transcript of a messaging session between a user of the electronic device and at least one other user, a plurality of electronic stickers, and a message-input area, detects a drag gesture that starts while a focus selector is at a first location in the messaging user interface that corresponds to an electronic sticker in the plurality of electronic stickers, and in response, moves the electronic sticker in the first direction in accordance with movement of the drag gesture. Upon termination of the drag gesture while the focus selector is at a second location in the messaging user interface, if the second location is within the conversation transcript, the electronic device places the electronic sticker in the conversation transcript at a location based on the second location, and otherwise ceases to display the electronic sticker.

Abstract: Introduced here is a technology that enables a merchant to create customer-targeted, customized communications by use of a merchant platform executing on a financial service system. The merchant platform generates content for communications that is based on a particular customer segment. The customer segment includes one or more groups of customers segmented based on one or more attributes associated with each group of customers. An attribute is determined based on data collected by the financial service system, where the data is related to transaction data of a plurality of merchants.

Abstract: Provided herein are pharmaceutically acceptable compositions containing macrolide antibiotics, in particular azithromycin. In particular, compositions containing azithromycin with low toxicity, especially for administration to felines, are provided herein.

Abstract: Provided herein are pharmaceutically acceptable compositions containing macrolide antibiotics, in particular azithromycin. In particular, compositions containing azithromycin with low toxicity, especially for administration to felines, are provided herein.

Abstract: Provided herein are pharmaceutically acceptable compositions containing macrolide antibiotics, in particular azithromycin. In particular, compositions containing azithromycin with low toxicity, especially for administration to felines, are provided herein.

Abstract: Provided herein are pharmaceutically acceptable compositions containing macrolide antibiotics, in particular azithromycin and tulathromycin. In particular, compositions containing azithromycin or tulathromycin with low toxicity, especially for administration to canines, are provided herein.

Abstract: Provided herein are pharmaceutically acceptable compositions containing macrolide antibiotics, in particular azithromycin. In particular, compositions containing azithromycin with low toxicity, especially for administration to felines, are provided herein.

Abstract: Provided herein are pharmaceutically acceptable compositions containing macrolide antibiotics, in particular azithromycin. In particular, compositions containing azithromycin with low toxicity, especially for administration to felines, are provided herein.

Abstract: Provided herein are pharmaceutically acceptable compositions containing macrolide antibiotics, in particular azithromycin. In particular, compositions containing azithromycin with low toxicity, especially for administration to felines, are provided herein.

Abstract: Provided herein are pharmaceutically acceptable compositions containing macrolide antibiotics, in particular azithromycin. In particular, compositions containing azithromycin with low toxicity, especially for administration to felines, are provided herein.

Abstract: Provided herein are pharmaceutically acceptable compositions containing macrolide antibiotics, in particular azithromycin and tulathromycin. In particular, compositions containing azithromycin or tulathromycin with low toxicity, especially for administration to canines, are provided herein.

Abstract: Provided herein are pharmaceutically acceptable compositions containing macrolide antibiotics, in particular azithromycin. In particular, compositions containing azithromycin with low toxicity, especially for administration to felines, are provided herein.

Abstract: A microprocessor controlled electronic subsystem for monitoring either a thermoelectric cooler or a laser diode and adjusting the thermoelectric cooler to compensate for temperature effects. The microprocessor, with the aid of a temperature sensor, monitors the current temperature of the thermoelectric cooler or laser diode and then chooses an appropriate target value to minimize the amount of time needed to drive the thermoelectric cooler or the laser to the appropriate temperature. The microprocessor contains software whose purpose is to choose the appropriate target value in order to fine tune the control response of the entire system. The system also includes the ability to pick a new target value if the environment or ambient temperature is beyond designed for values.